Everything below concerns research chemical. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-03-17. Where a claim depends on a specific study, the study is described rather than over-claimed.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
Quality assessment rests on two separate questions: whether the chain is the intended one, and how much of the sample is that chain. Reverse-phase high-performance liquid chromatography with ultraviolet detection is the standard purity measurement, while mass spectrometry confirms identity through the observed molecular mass. Amino acid analysis and sequence verification provide further checks. A reported purity percentage describes the proportion of the sample represented by the main peak, not the amount of peptide by mass, since counter-ions and water make up part of any lyophilized lot.
In its usual supplied form, the peptide is a white to off-white lyophilized powder that dissolves readily in water and in aqueous buffers. Powder keeps far longer than solution, so material is normally shipped and stored dry, then dissolved only when needed. Once in solution, the chain is subject to hydrolysis and the liquid supports microbial growth, and practical guidance generally treats the dissolved form as short-lived. Containers should stay sealed and desiccated, because the powder takes up moisture from air.
Long-term storage of the dry powder is typically described at minus twenty degrees Celsius or colder, while shorter holding periods may use ordinary refrigeration. Repeated warming and cooling cycles are discouraged because they stress the material and can promote aggregation or loss. Light exposure and residual moisture are both treated as avoidable sources of degradation, and working aliquots are often prepared to limit how many times a container is opened. Sealed vials with a desiccant are the usual container.
| Property | Value | Notes |
|---|---|---|
| Main study model | Rodents, rats and mice | Underpins most of the published data |
| Common routes in studies | Subcutaneous, intraperitoneal, oral | Varies with the experimental design |
| Common analytical method | Reversed-phase HPLC, LC-MS | Used for identity and purity checks |
| Human evidence base | Small | Few trials reported, with limited findings |
| Regulatory status | Varies by jurisdiction | Not an approved medicine in most places |
Lyophilized material is generally kept cold, commonly at minus twenty degrees Celsius, and shielded from moisture and light. Solutions are less stable than the dry powder, so repeated freeze-thaw cycles are avoided by splitting the material into single-use portions. Published stability data for this particular peptide are limited, which means suggested hold times should be read as provisional. Long-term refrigeration of reconstituted solutions is not well supported by available evidence.
Identity and purity are checked with standard peptide techniques. Reversed-phase high-performance liquid chromatography separates the main peak from closely related impurities and yields a percentage purity. Mass spectrometry confirms that the measured mass matches the theoretical value. Amino acid analysis offers an independent check on overall composition. These analytical methods characterize the material itself and reveal nothing about how it behaves in a living system.
In its common research form the peptide is supplied as a lyophilized powder. It dissolves readily in water and in typical aqueous buffers, which simplifies preparation of working solutions. Laboratories usually prepare small aliquots instead of one large volume. The dry material appears as a white to off-white solid with no distinctive odor. Bulk quantities are typically shipped in sealed vials.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
BPC-157 is a synthetic peptide built from fifteen amino acid residues. Its sequence comes from a larger protein fragment that researchers isolated from human gastric juice and described as a body protection compound. The fragment contains glycine, glutamic acid, five prolines, lysine, alanine, two aspartic acids, leucine, and valine. The number 157 in the name refers to the position of the stretch within the parent protein. Material used in laboratories is manufactured rather than extracted from stomach fluid.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
== Similarities with TCA cycle == The glyoxylate cycle uses five of the eight enzymes associated with the tricarboxylic acid cycle: citrate synthase, aconitase, succinate dehydrogenase, fumarase, and malate dehydrogenase. The two cycles differ in that in the glyoxylate cycle, isocitrate is converted into glyoxylate and succinate by isocitrate lyase (ICL) instead of into α-ketoglutarate. This bypasses the decarboxylation steps that take place in the citric acid cycle (TCA cycle), allowing simple carbon compounds to be used in the later synthesis of macromolecules, including glucose. Glyoxylate is subsequently combined with acetyl-CoA to produce malate, catalyzed by malate synthase. Malate is also formed in parallel from succinate by the action of succinate dehydrogenase and fumarase. The difference between the two cycles can be seen through their net equations. In the citric acid cycle, two carbons that are part of the acetyl-CoA are lost as carbon dioxide, which results in net carbon loss. Unlike the citric acid cycle, the glyoxylate cycle bypasses the two decarboxylations. This allows the glyoxylate cycle the net synthesis of glucose from acetyl-CoA. The net equation of the glyoxylate cycle is: 2Acetyl-CoA + NAD+ + 2H2O → Succinate + 2CoA + NADH + H+.
Ice-nine is a fictional material that appears in Kurt Vonnegut's 1963 novel Cat's Cradle. Ice-nine is described as a polymorph of ice which instead of melting at 0°C (32°F) melts at 45.8°C (114.4°F). When ice-nine comes into contact with liquid water below 45.8°C, it acts as a seed crystal and causes the solidification of the entire body of water, which quickly crystallizes as more ice-nine. As humans are 55-60% water, ice-nine kills nearly instantly when ingested or brought into contact with soft tissues exposed to the bloodstream, such as the eyes or lips. In the story, ice-nine is invented by Dr. Felix Hoenikker while working on the Manhattan Project in response to a suggestion from a Marine general, who complained about soldiers having to deal with mud on the battlefield. The project is abandoned when it becomes clear that any quantity of the substance would have the power to destroy all life on Earth. In the novel's climax, the Earth's oceans are accidentally frozen solid by ice-nine, prompting a doomsday scenario. Vonnegut encountered the idea of ice-nine while working at General Electric. He attributes the idea of ice-nine to his brother Bernard Vonnegut, who was researching the formation of ice crystals in the atmosphere. A later account of the events attributes the idea to the chemist Irving Langmuir, who devised the concept while helping H.G. Wells conceive ideas for stories. Vonnegut decided to adapt the idea into a story after Langmuir's death in 1957.
== Harvesting from cochineals == Carminic acid is commonly harvested from an American species scaled insects called Dactylopius coccus (or cochineals). Cochineals are parasitic scaled insects which are abundantly found on their host plants, the prickly pear cactus native to Mexico and South America. The insects are either cultivated or harvested from wild populations, mainly for the wingless females of the species which attach themselves to the cactus and outnumber the winged males of the species two hundred to one. Classically, cultivated species were grown from eggs placed by workers onto the cactus leaves and left to grow. There the female cochineals would remain immobile for about 3 months until being brushed off, collected, and dried for shipping. Females possess concentrations of about 1.5% bodyweight of carminic acid and newborns about 3.0%. The carminic acid is then extracted by soaking the dried cochineals in water, and additives are then added to alter dye colour and enable the dye to adhere to objects.
=== Decay by two or more processes === Some quantities decay by two exponential-decay processes simultaneously. In this case, the actual half-life T½ can be related to the half-lives t1 and t2 that the quantity would have if each of the decay processes acted in isolation:
Pat Striker (パトストライカー, Pato Sutoraikā): Deka Red's personal six-wheeled, police car-themed Deka Machine that forms the head and torso of Dekaranger Robo. It is also equipped with a pair of Striker Arms (ストライカーアーム, Sutoraikā Āmu), which allows it to wield the Judgement Sword (ジャッジメントソード, Jajjimento Sōdo) in its Driving Sword (ドライビングソード, Doraibingu Sōdo) formation. Pat Gyrer (パトジャイラー, Pato Jairā): Deka Blue's personal autogyro-themed Deka Machine that forms the left leg of Dekaranger Robo. It is also equipped with the Gyro Vulcan (ジャイロバルカン, Jairo Barukan) Gatling guns, the Gyro Wapper (ジャイロワッパー, Jairo Wappā) handcuffs, and the Magnet Wire (マグネワイヤー, Magune Waiyā). PaTrailer (パトレーラー, Patorērā): Deka Green's personal armored semi-trailer truck-themed Deka Machine that forms the right leg of Dekaranger Robo. It also carries the Judgement Sword and the Signal Cannon (シグナルキャノン, Shigunaru Kyanon) into battle. Pat Armor (パトアーマー, Pato Āmā): Deka Yellow's personal armored car-themed Deka Machine that forms the right arm of Dekaranger Robo. It is also equipped with floodlights, which allow it to perform the Armor Attack (アーマーアタック, Āmā Atakku) and Light Flash (ライトフラッシュ, Raito Furasshu) attacks. Pat Signer (パトシグナー, Pato Shigunā): Deka Pink's personal buggy-themed Deka Machine that forms the left arm of Dekaranger Robo. It is also equipped with a large retractable signboard.
Sources: en.wikipedia.org
Sam Chun Dang Pharm Co., Ltd. (Korean: 삼천당제약; Hanja: 三千堂製藥; RR: Samcheondang jeyak), commonly abbreviated as SCD, is a South Korean pharmaceutical company engaged in the development, manufacturing, and sale of prescription medicines. Founded in 1943, the company is headquartered in Seocho-gu, Seoul, with manufacturing operations at the Hyannam Pharmaceutical Industrial Complex in Hwaseong, Gyeonggi Province. SCD is listed on the Korea Exchange (KRX: 000250). The company is best known for its ophthalmic products, which accounts for approximately half of its total revenues, and has attracted attention for its development of an aflibercept biosimilar (SCD411) and an oral semaglutide generic.
Hexobarbital or hexobarbitone, sold both in acid and sodium salt forms as Citopan, Evipan, and Tobinal, is a barbiturate derivative having hypnotic and sedative effects. It was used in the 1940s and 1950s as an agent for inducing anesthesia for surgery, as well as a rapid-acting, short-lasting hypnotic for general use, and has a relatively fast onset of effects and short duration of action. Modern barbiturates (such as Thiopental) have largely supplanted the use of hexobarbital as an anesthetic, as they allow for better control of the depth of anesthesia. Hexobarbital is still used in some scientific research.
=== Other considerations === Also, the scientific community has raised critical questions about the validity of PDCAAS (the validity of the preschool-age child amino acid scoring pattern, the validity of the true fecal digestibility correction and the truncation of PDCAAS values to 100%).
== Substrates and interactions == PKC-epsilon has a wide variety of substrates, including ion channels, other signalling molecules and cytoskeletal proteins. PKC-epsilon has been shown to interact with:
Sources: en.wikipedia.org
The signal change manifests itself in an increase or decrease in the current (electrical) or in a change in the intensity or wavelength of the fluorescence emission (optical). Depending on the type of application, both electrical or optical signal transmission can be advantageous. For sensitive measurement of electronic changes, field-effect transistors (FET) are often used in which the flow of charges within the SWCNTs is measured. The FET structures allow easy on-chip integration and can be parallelized to detect multiple target analytes simultaneously. However, such sensors are more invasive for in vivo applications, as the entire device has to be inserted into the body. Optical detection with semiconducting SWCNTs is based on the radiative recombination of excitons in the near-infrared (NIR) by prior optical (fluorescence) or electrical excitation (electroluminescence). The emission in the NIR enables detection in the biological transparency window, where optical sensor applications benefit from reduced scattering and autofluorescence of biological samples and consequently a high signal-to-noise ratio. Compared to optical sensors in the UV or visible range, the penetration depth in biological tissue is also increased. In addition to the advantage of a contactless readout SWCNTs have excellent photostability, which enables long-term sensor applications. Furthermore, the nanoscale size of SWCNTs allows dense coating of surfaces which enables chemical imaging, e.g. of cellular release processes with high spatial and temporal resolution.
Cristina Alicia Taylor, Philanthropist and Co-Founder, The Taylor Family Foundation. For charitable services to Children and Young People. Judith Weir, , Master of the King's Music. For services to Music
=== Naturally-derived hydrogel dressings === Polysaccharide-based hydrogel dressings have been synthesized from polymers such as hyaluronic acid, chitin, chitosan, alginate, and agarose. Naturally-derived protein/proteoglycan hydrogel dressings have been synthesized from polymers such as collagen, gelatin, kappa-carrageenan, and fibrin.
== Pharmacodynamics == The molecule has the property of optimizing the microcirculatory function. In fact, it reduces capillary permeability both by stabilizing the basement membrane for an action on the collagen chains that constitute it, and by interacting with different biochemical mediators that favor endothelial permeability itself. In this way it favors a reduction in blood hyperviscosity and also performs an anti- platelet aggregation action.
The majority of them fled to the US or the UK, providing an extra impulse to the scientific dynamism of those nations. These movements ultimately made molecular biology a truly international science from the very beginnings.
Sources: en.wikipedia.org
Animal experiments form the bulk of the published record. Rodent models of tendon, ligament, bone, and gut injury are the most common designs. Controlled human trials are rare, which limits confidence in any clinical claim.
They are best described as working hypotheses. Supporting data come mainly from cell cultures and animal tissue, using markers such as growth factors and inflammatory signals. Confirmatory human studies have not been reported.
Status depends on the country. In some places it is treated as a research chemical available without a prescription, while elsewhere it falls under prescription or controlled rules. It holds no general marketing approval as a therapeutic product.
The dry powder is the stable form and the dissolved form is comparatively fragile. Freezing a solution slows degradation but does not stop it, and repeated freezing and thawing adds further stress. Many laboratories therefore prepare small single-use portions rather than storing one large volume.